XERSXeris Biopharma Holdings, Inc.
$10.48+36% 1Y
$10.48
$5.2952 weeks$10.48
Latest close: a new 52-week highOct 9, 2026what changed →
The financials
Xeris Biopharma Holdings, Inc. by the numbers
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $92M in Q2 2026 (quarter ended Jun 30, 2026), up 29% from the same quarter a year earlier. That came with a gross margin of 86% and net loss of $31M. For the full year FY2025, revenue was $292M (+44% year on year) and net income $554K. Its largest product in Q2 2026 was Recorlev at $57M, 62% of the disclosed total, well ahead of Gvoke at 24%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $92M | $72M | +29% |
| Gross profit | $80M | $60M | +33% |
| Operating income | $5.2M | $4.5M | +15% |
| Net income | −$31M | −$1.9M | n/a |
| Diluted EPS | −$0.18 | −$0.01 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Recorlev | $57M | 62% |
| Gvoke | $23M | 24% |
| Keveyis | $12M | 13% |
| Royalty Contract And Other | $1.1M | 1.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $92.1M (+11%)
Recorlev grew +81% year on yearProduct Other -100% year on year
Segment Latestquarter on quarteryear on year
- Recorlev$56.8M$56.8Mquarter on quarter +14%year on year +81%+14%+81%
- Gvoke$22.5M$22.5Mquarter on quarter +8.4%year on year -3.9%+8.4%-3.9%
- Keveyis$11.7M$11.7Mquarter on quarter -1.8%year on year +1.7%-1.8%+1.7%
- Royalty Contract And Other$1.1M$1.1Mquarter on quarter +63%year on year -71%+63%-71%
- Product Other$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore